<DOC>
	<DOCNO>NCT00005612</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy autologous peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat patient ovarian epithelial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity potential efficacy high dose chemotherapy ( HDC ) comprise etoposide , topotecan , carboplatin ( ETC ) follow autologous stem cell transplantation patient ovarian epithelial cancer . II . Determine maximum tolerate dose topotecan combine etoposide carboplatin patient . III . Determine disease free survival ( DFS ) overall survival ( OS ) patient treat regimen . IV . Measure amount subcellular location DNA topoisomerase I II- alpha ovarian cancer biopsy HDC relapse determine role alteration topoisomerases drug resistance ovarian cancer . V. Correlate amount location enzymes HDC clinical outcome ( DFS OS ) plasma concentration topotecan carboplatin patient . VI . Correlate level signal transducer activator transcription ( STAT ) expression bcl-2 family proteins response chemotherapy clinical outcome ( DFS OS ) patient . VII . Measure level STAT determine expression bcl-2 family proteins tumor biopsy HDC relapse determine role cellular pathway drug response . VIII . Determine pharmacokinetic pharmacodynamic relationship high dose topotecan combine carboplatin patient . OUTLINE : This dose escalation study topotecan . Mobilization : After completion salvage chemotherapy within 6 week second look laparotomy , patient receive cyclophosphamide IV 2 hour paclitaxel IV 2 hour 2 day . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin 24 hour completion chemotherapy continue autologous peripheral blood stem cell ( PBSC ) harvest select CD34+ cell . High dose chemotherapy : After prim chemotherapy within 6 week second look laparotomy , patient receive carboplatin IV 1 hour day -8 -6 ; topotecan IV 30 minute day -7 -5 ( begin 12 hour completion carboplatin infusion ) ; etoposide IV 4 hour day -5 -3 ( begin 12 hour completion last topotecan infusion ) . Cohorts 4-12 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 6 12 patient experience dose limit toxicity . Transplantation : PBSC reinfused day 0 . Patients follow 3 6 month , annually thereafter . PROJECTED ACCRUAL : Approximately 4-30 patient accrue study within 3-4 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIIC ovarian epithelial cancer Chemosensitive 68 course standard dose adjuvant chemotherapy ( one regimen ) , cisplatin carboplatin combination paclitaxel , standard dose regimen Residual disease ( great 1 cm ) follow second look laparotomy Ineligible microscopic disease present follow induction chemotherapy OR Histologically proven newly diagnose stage IV ovarian epithelial cancer Achieved least partial response ( PR ) ( 80 % great reduction tumor CT scan ) follow six course standard dose chemotherapy ( one regimen ) OR Residual disease ( great 1 cm ) disease determine time second look laparotomy OR Histologically proven relapse ovarian epithelial cancer Relapse follow standard dose chemotherapy Chemosensitive Achieved least PR 46 course salvage chemotherapy ( total 2 regimen ) No six week interval completion standard dose chemotherapy second look laparotomy PATIENT CHARACTERISTICS : Age : 18 65 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL ALT AST great 2.5 time normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : Ejection fraction least 50 % MUGA scan No severe cardiac dysfunction major heart disease No angina pectoris No ventricular dysrhythmias Essential hypertension allow control medication ( ) Pulmonary : DLCO least 50 % predict No symptomatic obstructive restrictive pulmonary disease Other : No active infection HIV negative No uncontrolled insulin dependent diabetes mellitus No uncompensated major thyroid adrenal dysfunction No malignancy within past 5 year except nonmelanomatous skin cancer Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior topotecan Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent nitroglycerin preparation antiarrhythmic drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>